Market Overview

Gamida Cell Announces Pricing of Initial Public Offering


Cell Ltd.
, a leading cellular and immune therapeutics company, today
announced the pricing of its initial public offering of 6,250,000
ordinary shares at a public offering price of $8.00 per share for
aggregate gross proceeds of $50.0 million. All of the shares in the
offering are being offered by Gamida Cell. In addition, Gamida Cell
granted the underwriters a 30-day option to purchase up to 937,500
additional ordinary shares at the initial offering price, less
underwriting discounts and commissions. Gamida Cell's ordinary shares
are expected to begin trading on the Nasdaq Global Market on October 26,
2018, under the ticker symbol "GMDA." The offering is expected to close
on or about October 30, 2018, subject to customary closing conditions.

BMO Capital Markets and RBC Capital Markets are acting as joint
book-running managers for this offering. Needham & Company and
Oppenheimer & Co. are acting as co-lead managers for this offering.

A registration statement relating to these securities was declared
effective by the Securities and Exchange Commission on October 26, 2018.
This offering will be made only by means of a prospectus. Copies of the
final prospectus related to this offering may be obtained, when
available, from: BMO Capital Markets, 3 Times Square, New York, NY
10036, Attention: Equity Syndicate Department, Telephone: (800)
414-3627, Email:;
or RBC Capital Markets, 200 Vesey Street, 8th Floor, New York, NY 10281,
Attention: Equity Syndicate Department, Telephone: (877) 822-4089,

This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or

About Gamida Cell
Gamida Cell is a clinical stage
biopharmaceutical company leveraging its proprietary technology to
develop cell therapies that are designed to cure cancer and rare,
serious hematologic diseases. The company is leveraging its
nicotinamide-, or NAM-, based cell expansion technology to develop a
pipeline of products designed to address the limitations of cell

Forward Looking Statements
This press release contains
forward-looking statements, including with respect to the expected
closing of Gamida Cell's initial public offering. These forward-looking
statements are subject to a number of risks, uncertainties and
assumptions, including that the conditions to the closing of the initial
public offering are not satisfied. Gamida Cell undertakes no obligation
to update any such forward-looking statements after the date hereof,
except as required by law.

View Comments and Join the Discussion!